Literature DB >> 10358791

An overview of tumor necrosis factor alpha and the failing human heart.

G Torre-Amione1, B Bozkurt, A Deswal, D L Mann.   

Abstract

Recent studies have identified the importance of biologically active molecules (e.g., neurohormones) in disease progression in heart failure. In addition to neurohormones, another portfolio of biologically active molecules, termed cytokines, are also expressed in the setting of heart failure. This article reviews recent clinical and experimental material that suggest that the cytokines (e.g., tumor necrosis factor alpha), much like the neurohormones, may represent another class of biologically active molecules that are responsible for the development and progression of heart failure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358791     DOI: 10.1097/00001573-199905000-00003

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  14 in total

1.  Inflammation-mediated rheumatic diseases and atherosclerosis.

Authors:  S Manzi; M C Wasko
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

2.  Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters.

Authors:  Tomie Kawada; Mikio Nakazawa; Sakura Nakauchi; Ken Yamazaki; Ryoichi Shimamoto; Masashi Urabe; Jumi Nakata; Chieko Hemmi; Fujiko Masui; Toshiaki Nakajima; Jun-Ichi Suzuki; John Monahan; Hiroshi Sato; Tomoh Masaki; Keiya Ozawa; Teruhiko Toyo-Oka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Fatigue, inflammation, and projected mortality in heart failure.

Authors:  Anne M Fink; Rosalia C Gonzalez; Tadeusz Lisowski; Maria Pini; Giamila Fantuzzi; Wayne C Levy; Mariann R Piano
Journal:  J Card Fail       Date:  2012-09       Impact factor: 5.712

4.  Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases.

Authors:  L'ubomír Tomáš; Ivica Lazúrová; Lýdia Pundová; Mária Oetterová; Mária Zakuciová; Darina Petrášová; Martin Studenčan
Journal:  Clin Rheumatol       Date:  2012-09-26       Impact factor: 2.980

Review 5.  Optimising management of patients with advanced heart failure: the importance of preventing progression.

Authors:  B Stanek
Journal:  Drugs Aging       Date:  2000-02       Impact factor: 3.923

Review 6.  Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease.

Authors:  Qurat-ul-ain Jelani; Stuart D Katz
Journal:  Cardiol Rev       Date:  2010 Sep-Oct       Impact factor: 2.644

7.  Cardio-renal anemia syndrome.

Authors:  G Efstratiadis; D Konstantinou; I Chytas; G Vergoulas
Journal:  Hippokratia       Date:  2008-01       Impact factor: 0.471

Review 8.  Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Mauro Galeazzi; Franco Laghi-Pasini
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  Biomarker profile in stable Fontan patients.

Authors:  Anita Saraf; Christine De Staercke; Ian Everitt; Alice Haouzi; Yi-An Ko; Staci Jennings; Jonathan H Kim; Fred H Rodriguez; Andreas P Kalogeropoulos; Arshed Quyyumi; Wendy Book
Journal:  Int J Cardiol       Date:  2020-01-09       Impact factor: 4.164

Review 10.  Autoimmunological features in inflammatory cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Andrea Dörner; Wolfgang-Christian Poller; Michel Noutsias; Uwe Kühl; Heinz-Peter Schultheiss; Mathias Pauschinger
Journal:  Clin Res Cardiol       Date:  2007-05-22       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.